PERSONAL PROTECTION AGAINST BITING INSECTS AND TICKS
PPAV WORKING GROUPS*

Summary:
Recent events with the first cases of local transmission of chikungunya and dengue fever virus in southern France by Aedes albopictus, adding to the nuisance and potential vectors that can be encountered when traveling in tropical or sub-tropical countries, has shown the value of a reflection on the Personal protection against vectors (PPAV). It is seen during an outbreak of vector-borne disease, or simply because of nuisance arthropods, that our fellow citizens try to protect themselves individually by using an arsenal of resources available on the market. Yet most of these means have been neither checked for effectiveness or safety tests, however, essential. Travellers, staff on mission or assignment, are looking for specific information on how to protect themselves or their families. Health workers had at their disposal so far indications that vary widely from one source to another. Therefore it seemed important to the Society of Travel Medicine (SMV) and the French Society of Parasitology (SFP) to initiate a reflection on this theme. This reflection took the form of recommendations for good practice, following the outline established by the French High Health Authority (HAS). The aim was to gather all relevant information, verified and validated and the format to be used not only by health personnel (doctors, pharmacists, nurses), but also by travel agents and individuals. This document highlights the need to take into account the risk of vector-borne diseases, some deadly, and the benefit of various methods of personal protection. The choice of methods is clearly oriented towards those whose effectiveness has been proven and potential risks assessed. The paper finally proposes two decision trees based on the transmission type (day or night) and kind of stay (short or roaming, long and steady). It concerns travellers, but also expatriates, residents and nomads.

KEY WORDS: vector borne diseases, personal protection, vectors, recommendations for good practice.

This recommendation has been awarded by the professional HAS. This label means that the recommendation was developed according to procedures and methodological rules recommended by the High Authority for Health (HAS). Any dispute on the merits should be paid directly from the developer.

* “Personal Protection Against Vectors” working groups, whose members are listed in pages 110-111.
Corresponding authors:

1. Prof. Gérard Duvallet, UMR 5175 CEFE, Université Montpellier 3, 34199 Montpellier Cedex 5, France.
E-mail: gerard.duvallet@univ-montp3.fr

2. Dr Ludovic de Gentile, Laboratoire de Parasitologie-Mycologie, Unité de médecine des voyages, Centre hospitalier universitaire, 49933 Angers Cedex 9, France.
E-mail: LuDeGentile@chu-angers.fr

Résumé : PROTECTION PERSONNELLE CONTRE LES INSECTES PIQUEURS ET LES TIQUES
L’actualité récente avec les premiers cas de transmission autochtone par Aedes albopictus des virus chikungunya et de la dengue dans le sud de la France continentale, s’ajoutant aux nuisances et vecteurs potentiels que l’on peut rencontrer lors de voyages ou de missions plus ou moins longues dans les régions à climat chaud, a montré l’intérêt d’une réflexion approfondie sur la Protection personnelle anti-vectorielle (PPAV). Il est observé lors d’épidémie de maladie à transmission vectorielle ou en raison simplement des nuisances liées aux arthropodes, que nos concitoyens cherchent à se protéger individuellement en ayant recours à tout un arsenal de moyens disponibles sur le marché. Or la plupart de ces moyens n’ont fait l’objet ni de contrôles d’efficacité ni de contrôles d’innocuité, pourtant indispensables. Les voyageurs, les personnels envoyés en mission ou en affectation, sont à la recherche d’informations précises sur les moyens de protection pour eux-mêmes ou leurs familles. Les personnels de santé n’avaient à leur disposition jusqu’à présent que des indications très variables d’une source à une autre. C’est pourquoi il a semblé important à la Société de Médecine des Voyages (SMV) et la Société Française de Parasitologie (SFP) d’initier une réflexion sur ce thème. Cette réflexion a pris la forme de Recommandations de bonne pratique, en suivant le schéma élaboré par la Haute Autorité de Santé (HAS). L’objectif était de rassembler toutes les informations pertinentes, vérifiées et validées, et les mettre en forme pour être utilisées non seulement par les personnels de santé (médecins, pharmaciens, infirmiers), mais aussi par les agents touristiques et les particuliers. Ce document met en exergue la nécessité de prendre en compte le risque lié aux maladies à transmission vectorielle, dont certaines sont mortelles, et le bénéfice de différentes méthodes de protection personnelle. Le choix des méthodes est clairement orienté vers celles dont l’efficacité a été prouvée et les risques éventuels évalués. Le document propose finalement deux arbres décisionnels en fonction du type de transmission (diurne ou nocturne) et du type de séjour (courte ou itinérant, long et fixe). Il concerne les voyageurs, mais aussi les expatriés, les résidents et les nomades.

MOTS-CLÉS : maladies à transmission vectorielle, protection personnelle, arthropodes vecteurs, bonnes pratiques cliniques.

Cette recommandation professionnelle a reçu le label HAS. Ce label signifie que la recommandation a été élaborée selon les procédures et règles méthodologiques préconisées par la Haute Autorité de Santé (HAS).
Toute contestation sur le fond doit être portée directement auprès du promoteur.
Table of contents

Rationale
Introduction
General methodology
Evaluation of the recommendations
What are the vectors, harms, transmitted pathogens and diseases concerned by a Personal protection against vectors?

Text of recommendations
General measures for prevention
Role of cutaneous repellents in PPAV
Role of impregnated mosquito nets in PPAV
Role of impregnated clothes and fabrics in PPAV
Additional measures in PPAV
Consideration of particular fields for PPAV
Acceptable risks associated to the use of a PPAV
Long-term deleterious effects of PPAV measures
Risks for human health in relation with harms and protection means
Personal protection strategies according to the disease, duration of the stay and psycho-social and economical impact of the protection means

Organizing committee
Workgroup
External experts consulted for the workgroup
Reading Group

RATIONALE

INTRODUCTION

The chikungunya epidemics that were rife in Reunion Island in 2006 reminded the French population of the importance of fighting arthropods that serve as vectors for infectious agents. Nevertheless, the use of repellents and other protection means became gradually established in the advice to travelers for prevention of malaria and dengue, following recommendations of the “Comité des maladies du voyageur et d’importation” (CMVI), which relay the concerns of the World Health Organization (WHO). To draw a parallel with vector control concerns of the World Health Organization (WHO) and the “Société de médecine des voyages” (SMV), which recently reviewed recommendations of the “Comité des maladies du voyageur et d’importation” (CMVI), which relay the concerns of the WHO and the “Société de médecine des voyages” (SMV), which recently reviewed current scientific literature on PPAVs and held a multidisciplinary discussion between experts. The consensus of the committee led to changes in the recommendations for clinical practices.

Financial support for this work was provided by the French “Direction générale de la santé”. This work has set the importance of PPAV, defines the procedure to follow at the individual level, and led to the redaction of documents targeting both health professionals and public. The recommendations are first and foremost for travelers, but also for people inhabiting areas at risk for the transmission of vector-borne diseases and nomadic populations crossing areas at risk. PPAV measures associated with vector control procedures include in-home spraying of remnant insecticides and installation of mosquito nets on windows and doors. During the preparation of this work, some observations were made that could impact regulation during the drug approval process. This collective production adds to the work coordinated by colleagues at the French “Institut de recherche pour le développement” (IRD) regarding vector control at both the adult and larva stages in France.

- General methodology

This document was written according to the method “Recommendations for clinical practice” (RCP) proposed by the French “Haute autorité de santé” (HAS). Four bibliographic research equations were used to search the Pubmed® system and have been set up with the documentation service of the French “Agence française de sécurité sanitaire et des produits de santé”. This bibliographic research was centered on means for personal protection (i.e. insecticides, impregnation of clothes, mosquito nets, and repellents), the arthropods targeted, the infectious agents transmitted and the diseases they cause. The members of the workgroup used these equations with the limits inherent to their particular question. The bibliographic research also included documents from national or international institutions and/or organizations that were available on their Internet sites.

1 Vector control : action against the vector of a pathogenic agent and not against the pathogenic agent itself. For instance: control of anopheles (the mosquito that vehiculates Plasmodium parasites) and not of Plasmodium itself (the protozoan responsible for the disease) to fight malaria.


**International organizations**
World Health Organization (WHO-OMS) and their agencies, particularly the Pesticides Evaluation Scheme (Whopes) and the service for International Travel and Health.

**National institutions**

**French:** Institut de veille sanitaire (InVS), Institut national de recherche et sécurité (Inrs), Agence française de sécurité sanitaire des produits de santé (Afssaps), Agence française de sécurité sanitaire de l’environnement et du travail (Afsset), Ministère de l’écologie, de l’environnement, du développement durable et de la mer (Meeddm), Ministère des affaires étrangères (Mae), Ministère de la santé et des sports (Mss), Direction générale de l’aviation civile (Dgac-France),

**Non-French:** Centers for Disease Control and Prevention (US-CDC), Environmental Protection Agency (US-EPA), Agency for Toxic Substances and Disease Registry (US-ATSDR), Agence de règlementation de lutte antiparasitaire (ARLA – Canada), Agence de santé publique du Canada, Health protection agency (HPA – Royaume Uni), National travel health network (Nathnc – Royaume Uni), Department of Health and ageing (Australie), Institut de médecine tropicale d’Anvers (Belgique).

In this document, for each addressed question, the novel recommendation and proof for each proposed measure are reported in a rating grid, adapted from Kisch.

- Evaluation of the recommendations

The proposed recommendations are rated A, B, or C according to the following criteria:

Grade A recommendations are based on results from scientific studies with a high level of proof. These studies would include comparative, randomized studies of high power without major biases, meta-analyses of comparative, randomized tests, and decision analysis based on well-performed studies (level of proof 1).

Grade B recommendations are based on a scientific presumption generated by studies with an intermediate level of proof, such as comparative, randomized tests of low power, comparative but non-randomized, well-performed tests, and cohort studies (level of proof 2).

Grade C recommendations are based on lower-level studies, such as case-control studies (level of proof 3), or retrospective studies, series of cases and comparative studies with high-level biases (level of proof 4).

The recommendations without grade result from an agreement within the workgroup, based on their professional experience and after consultation of the reading group. They concern cases for which documentation was not available.

**WHAT ARE THE VECTORS, HARMs, TRANSMITTED PATHOGENS AND DISEASES CONCERNED BY A PERSONAL PROTECTION AGAINST VECTORS?**

Arthropods form a vast group of extremely diverse invertebrates (Crustaceans, Arachnids, Myriapods, Insects, etc...), of which some species play an essential role in human pathologies. The differentiation between harmful and vector arthropods are often ambiguous: some species can successively or simultaneously belong to both categories.

The notion of harm refers to discomfort, blood spoliation, inflammation caused by stinging or biting, and allergic or dermatologic consequences related to the contact with an arthropod.

A restrictive definition states that a vector is “all hematophagous arthropod that is responsible for the active biological transmission of a pathogenic agent from one vertebrate to another.” A wider definition comprises all hematophagous arthropods that are responsible for the biological or mechanical transmission of a pathogenic agent from one vertebrate to another.

At the individual level, the tools used for protection against harmful insects and vectors are the same. However, in the risk analysis, the protection from a vector must take into account the risk related to the transmitted infectious agent. The principal vectors belong to the vast groups of insects and acari (ticks and mites).

Vector-born human and zoonotic diseases are numerous and are due to a large variety of infectious, pathogenic agents: viruses (e.g. chikungunya, yellow fever, dengue, etc...), bacteria (e.g. Lyme borreliosis, plague, etc...), protozoans (e.g. malaria, sleeping sickness, Chagas disease, leishmaniosis, etc...) or metazoans (e.g. loiasis, Bancroft’s filariasis, etc...).

These diseases are rife mostly in tropical areas but temperate areas are not free from them. The classical triad (host, vector, infectious agent) is associated in a vectorial system that works in a particular environment that is perpetually being modified.

The following tables sum up the indispensable knowledge about vectors.

---

5 Biological transmission implies the modification and/or the multiplication of the organism within the vector. Once infected during an infecting blood meal, the biological vector generally remains infected for its whole life.
6 Mechanical transmission does not imply the modification and/or the multiplication of the organism within the vector. The vector only acts as a self-mobile needle. It is generally the case during an interrupted blood meal on an infected host that is resumed rapidly on a receptive host.
7 Zoonosis is an infectious disease whose agent can be transmitted from animals to humans, formerly known as anthropozooonosis.
### Classes | Orders | Families | Hematophagous stages | Biology of the hematophagy | Preimaginal stages
---|---|---|---|---|---
**Diptera** | **Insects** | **Calicidae** (mosquitoes) | Adult females | Principally crepuscular for *Aedes*; Principally nocturnal for *Anopheles, Culex* and *Mansonia* | Water (stagnant or calm)
**Simulidae** (black flies) | **Siphonaptera** (fleas) | Adult females | Diurnal | Water (running)
**Psychodidae** (sand flies) | **Hemiptera** (typical bugs) | Adult females | Nocturnal | Land (humus, animal litters)
**Tabanidae** (horse flies) | **Anoplura** (lice) | Adult females | Diurnal | Semi-aquatic
**Ceratopogonidae** | **Acarina** (ticks) | Adult females | Mainly crepuscular but variable among species | Land (humus)
**Glossinidae** (tsetse flies) | **Ixodidae** (hard ticks) | Adult males and females | Diurnal | *In utero* except land pupa
**Siphonaptera** (fleas) | Numerous families | Adult males and females | Several blood meals per day | Land (litters)
**Hemiptera** | **Heteroptera** (typical bugs) | **Reduviidae** (*Rhodnius, Triatoma*) | Adult males and females, and immatures | Nocturnal | Land Hematophagous
**Anoplura** | **Acarina** (ticks) | **Pediculicidae** (lice) | Adult males and females, and immatures | Several blood meals per day | Land Hematophagous

### Table I. – Principal vectors (insects and ticks).

| Common points | *Anopheles* | *Aedes* | *Culex*
---|---|---|---
Hematophagy | Only adult females are hematophagous | | |
Number of blood meals | Each female generally takes several blood meals during its life, that can last several months | | |
Egg clutch | After the digestion of a blood meal, the female clutches eggs in water collections | | |

### Differences

| Common points | *Anopheles* | *Aedes* | *Culex*
---|---|---|---
Preferential habitat | Preferentially rural but also suburban or urban, above all in Africa | Variable according to the species, but sometimes strictly urban | |
Day period of biting | Nocturnal (but some crepuscular species in South America) | Diurnal | Nocturnal
Modality of biting | A sole bite | Harasses its host until the meal is complete | Generally a sole bite
Flight type | Silent | Noisy | |
Aspect of the bite | Not painful, few inflammatory signs | Sensitive with inflammatory signs of more or less extent | |

Table II. – Principal traits on the comparative biology of *Anopheles, Aedes* and *Culex* mosquitoes.
Classification of methods for anti-vector protection

1) Protection technique: physical, biological, chemical, genetically
2) Target: larvae, adults
3) Effect sought by impairing:
   - host-vector contact: wearing of long-sleeved and long-legged clothes
   - cutaneous repellents
   - impregnated clothing (repellents-insecticides)
   - protection by domestic use of pesticides (aerosols, coils, etc...)
   - simple or impregnated mosquito nets for beds (repellents-insecticides)
   - vector density: reduction of larva nests by modification of their environment
   - larva control with biological larvicides (larvivorous fish), biopesticides (Bacillus thuringiensis) or chemical larvicides
   - impregnated bed mosquito nets used at high scale (mass effect)
   - spatial spraying
   - vector life-span: intra-domiciliary spraying
   - impregnated bed mosquito nets used at high scale (mass effect)
   - spatial spraying

Table III. – Principal methods for anti-vector protection against mosquitoes (from Carnevale, Robert et al. 2009)*.

* In this RGP document the only methods considered and evaluated were those that reduce host-vector contact.

<table>
<thead>
<tr>
<th>Geographic areas</th>
<th>Vector-borne diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northern Europe</td>
<td>European tick-borne encephalitis; Crimean–Congo hemorrhagic fever</td>
</tr>
<tr>
<td></td>
<td>Lyme borreliosis; Bartonellosis; Q fever</td>
</tr>
<tr>
<td></td>
<td>Babesiosis</td>
</tr>
<tr>
<td>Southern Europe</td>
<td>West Nile fever; Toscana virus infection; Chikungunya; Dengue</td>
</tr>
<tr>
<td></td>
<td>Lyme borreliosis; Boutonneuse fever (Mediterranean spotted fever); Bartonellosis; Q fever</td>
</tr>
<tr>
<td></td>
<td>Leishmaniosis</td>
</tr>
<tr>
<td>Northern Africa</td>
<td>West Nile fever; Toscana virus infection</td>
</tr>
<tr>
<td></td>
<td>Lyme borreliosis; Boutonneuse fever (Mediterranean spotted fever); Bartonellosis; Murine typhus; Epidemic typhus; Q fever; Pestis; Tick-borne relapsing fever</td>
</tr>
<tr>
<td></td>
<td>Leishmaniosis</td>
</tr>
<tr>
<td>Sub-Saharan Africa</td>
<td>Dengue; Yellow fever; Chikungunya; Rift Valley fever; Crimean–Congo hemorrhagic fever; West Nile fever</td>
</tr>
<tr>
<td></td>
<td>Tick-borne relapsing fever; African (Dutton’s) relapsing fever; Bartonellosis; Murine typhus; Epidemic typhus; Q fever; Pestis</td>
</tr>
<tr>
<td></td>
<td>Malaria; Human African trypanosomosis (sleeping sickness); Leishmaniosis</td>
</tr>
<tr>
<td></td>
<td>Lymphatic filariasis; Loaosis; Onchocercosis; Serous cavity filariosis (Mansonellosis)</td>
</tr>
<tr>
<td>South-Western Indian Ocean</td>
<td>Dengue; Chikungunya; Rift Valley fever</td>
</tr>
<tr>
<td></td>
<td>Pestis</td>
</tr>
<tr>
<td></td>
<td>Malaria</td>
</tr>
<tr>
<td></td>
<td>Lymphatic filariasis</td>
</tr>
<tr>
<td>Asia</td>
<td>Dengue; Chikungunya; Crimean–Congo hemorrhagic fever; Far Eastern tick-borne encephalitis; Japanese encephalitis</td>
</tr>
<tr>
<td></td>
<td>Scrub typhus; Murine typhus; Pestis</td>
</tr>
<tr>
<td></td>
<td>Malaria; Leishmaniosis</td>
</tr>
<tr>
<td></td>
<td>Lymphatic filariasis</td>
</tr>
<tr>
<td>Oceania</td>
<td>Dengue; Chikungunya; Japanese encephalitis; Ross River fever</td>
</tr>
<tr>
<td></td>
<td>Malaria</td>
</tr>
<tr>
<td></td>
<td>Lymphatic filariasis</td>
</tr>
<tr>
<td>Northern America</td>
<td>West Nile fever; Dengue</td>
</tr>
<tr>
<td></td>
<td>Lyme borreliosis; Rocky Mountain spotted fever; Ehrlichiosis; Pestis</td>
</tr>
<tr>
<td></td>
<td>Babesiosis</td>
</tr>
<tr>
<td>Latin America</td>
<td>Dengue; Yellow fever; West Nile Fever</td>
</tr>
<tr>
<td></td>
<td>Oroya fever (Carrión’s disease); Pestis; Epidemic typhus; Murine typhus</td>
</tr>
<tr>
<td></td>
<td>Malaria; Human American trypanosomosis (Chagas disease); Leishmaniosis</td>
</tr>
<tr>
<td></td>
<td>Serous cavity filariosis (Mansonellosis)</td>
</tr>
</tbody>
</table>

Table IV. – Principal vector-borne diseases with respect to geographic areas (1 = arbovirosis; 2 = bacteriosis; 3 = protozoosis; 4 = helminthiosis).
<table>
<thead>
<tr>
<th>Diseases</th>
<th>Agents</th>
<th>Vectors</th>
<th>Hosts-reservoirs</th>
<th>Distribution</th>
<th>Mode</th>
<th>Incidence in transmission area</th>
<th>Morbidity</th>
<th>Lethality</th>
<th>Tendency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dengue</td>
<td>Flaviviridae</td>
<td><em>Ae. aegypti</em>, <em>Ae. albopictus</em>, <em>Ae. polynesiensis</em></td>
<td>Men, vectors</td>
<td>Ubiquitous (Metropolitan France, FDA, Réunion, Mayotte, Polynesia included), except cold areas</td>
<td>Endemo-epidemic</td>
<td>High</td>
<td>Important</td>
<td>Yes</td>
<td>Expanding</td>
</tr>
<tr>
<td>Japanese encephalitis</td>
<td>Flaviviridae</td>
<td><em>Culex tritaeniorhynchus</em></td>
<td>Pigs, wild birds</td>
<td>Indian peninsula, Far East, South-Eastern Asia, Papua</td>
<td>Endemo-epidemic</td>
<td>High</td>
<td>Important</td>
<td>Yes</td>
<td>Expanding except in countries that have access to vaccination</td>
</tr>
<tr>
<td>West Nile fever</td>
<td>Flaviviridae</td>
<td>Mosquitoes <em>Culex sp.</em></td>
<td>Birds</td>
<td>All continents, of which Europe, Mediterranean area, Guadeloupe</td>
<td>Endemo-epidemic</td>
<td>Low</td>
<td>Potentially important in case of epidemics</td>
<td>Important</td>
<td>Expanding in Northern America and Mediterranean area</td>
</tr>
<tr>
<td>European tick-borne encephalitis</td>
<td>Flaviviridae</td>
<td>Ticks <em>Ixodes ricinus</em></td>
<td>Wild mammals, vectors</td>
<td>Central, Eastern and Northern Europe Eastern France</td>
<td>Endemic</td>
<td>Low</td>
<td>Important</td>
<td>Expanding in Eastern Europe Stable in French Metropole</td>
<td></td>
</tr>
<tr>
<td>Far-Eastern tick-borne encephalitis</td>
<td>Flaviviridae</td>
<td>Ticks <em>I. persulcatus</em></td>
<td>Mainly rodents</td>
<td>Far East and Siberia</td>
<td>Epidemic</td>
<td>Low</td>
<td>High</td>
<td>Important</td>
<td>Expanding</td>
</tr>
<tr>
<td>Yellow fever</td>
<td>Flaviviridae</td>
<td>Mosquitoes <em>Aedes sp.</em></td>
<td>Monkeys, vectors</td>
<td>Sub-Saharan Africa, Amazon (and Guyane)</td>
<td>Isolated cases</td>
<td>Epidemic (vaccination)</td>
<td>Important</td>
<td>High</td>
<td>Unstable*</td>
</tr>
<tr>
<td>Chikungunya</td>
<td>Togaviridae</td>
<td><em>Ae. aegypti</em>, <em>Ae. albopictus</em></td>
<td>Men, monkeys, vectors</td>
<td>Africa, Indian Ocean (and Réunion, Mayotte), Asia, Southern Europe and France (vaccination)</td>
<td>Epidemic</td>
<td>High</td>
<td>Important</td>
<td>None</td>
<td>Stable but better diagnosis</td>
</tr>
<tr>
<td>Toscana virus infection</td>
<td>Bunyaviridae</td>
<td>Sand flies</td>
<td>Men (other mammals), vectors</td>
<td>Mediterranean area Potentially: FDA, Pacific</td>
<td>Endemic</td>
<td>Low</td>
<td>Mild</td>
<td>None</td>
<td>Stable but better diagnosis</td>
</tr>
<tr>
<td>Rift Valley fever</td>
<td>Bunyaviridae</td>
<td>Mosquitoes <em>Culex, Aedes</em></td>
<td>Ruminants, vectors</td>
<td>Africa, Indian Ocean (and Mayotte)</td>
<td>Endemo-epidemic</td>
<td>Currently assessed in Mayotte</td>
<td>Important</td>
<td>Low</td>
<td>Expanding</td>
</tr>
<tr>
<td>Crimean–Congo hemorrhagic fever</td>
<td>Bunyaviridae</td>
<td>Ticks <em>Bunolaelaps</em>, of which <em>Hyalomma sp.</em></td>
<td>Wild mammals, vectors</td>
<td>Europe, Asia, Africa</td>
<td>Endemo-epidemic</td>
<td>Low</td>
<td>Important</td>
<td>High</td>
<td>Stable</td>
</tr>
</tbody>
</table>

Table V. – Principal human and zoonotic vector-borne infections, and their epidemiologic characteristics (non-exhaustive list). FDA = French departments in America. * documents of WHO for updated information.
<table>
<thead>
<tr>
<th>Diseases</th>
<th>Agents</th>
<th>Vectors</th>
<th>Hosts-reservoirs</th>
<th>Distribution</th>
<th>Mode</th>
<th>Incidence in transmission area</th>
<th>Morbidity</th>
<th>Lethality</th>
<th>Tendency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q fever or coxiellosis</td>
<td>Coxiella burnetii</td>
<td>Ticks</td>
<td>Mammals</td>
<td>Ubiquitous</td>
<td>Endemic</td>
<td>High</td>
<td>Important</td>
<td>Yes</td>
<td>Current epidemics in Netherlands, Stable elsewhere</td>
</tr>
<tr>
<td>Trench fever</td>
<td>Bartonella quintana</td>
<td>Body lice</td>
<td>Men</td>
<td>Ubiquitous</td>
<td>Endemic</td>
<td>High</td>
<td>Important</td>
<td>Yes</td>
<td>Expanding in homeless and highly precarious people</td>
</tr>
<tr>
<td>Oroya fever or Carrion’s disease</td>
<td>Bartonella bacilliformis</td>
<td>Sand flies</td>
<td>High valleys of Andes and intertropical area of Southern America</td>
<td>Endemic</td>
<td>High</td>
<td>Important</td>
<td>Yes</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>Lyme disease</td>
<td>Borrelia burgdorferi</td>
<td>Ticks Ixodes sp.</td>
<td>Rodents, deers, birds, vectors</td>
<td>Northern hemisphere</td>
<td>Endemic</td>
<td>High</td>
<td>Important</td>
<td>Very low</td>
<td>Expanding</td>
</tr>
<tr>
<td>Tick-borne relapsing fever</td>
<td>Borrelia crocidurine</td>
<td>Ticks Alectorobius sonrai</td>
<td>Rodents</td>
<td>Western Africa</td>
<td>Endemic</td>
<td>High</td>
<td>Important</td>
<td>Low</td>
<td>Stable</td>
</tr>
<tr>
<td>Louse-borne relapsing fever</td>
<td>Borrelia recurrentis</td>
<td>Body lice</td>
<td>Men</td>
<td>Potentially ubiquitous</td>
<td>Epidemic</td>
<td>High in refugee camps</td>
<td>High</td>
<td>High</td>
<td>Diminishing</td>
</tr>
<tr>
<td>Epidemic typhus</td>
<td>Rickettsia prowazekii</td>
<td>Body lice</td>
<td>Men</td>
<td>Ubiquitous, including African mountains and Latin America</td>
<td>Endemically</td>
<td>Important</td>
<td>Low</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>Boutonneuse fever (Mediterranean spotted fever)</td>
<td>Rickettsia conorii</td>
<td>Ticks Rhicophilus sanguineus</td>
<td>Vectors, dogs, rodents</td>
<td>Mediterranean area including South-Eastern France</td>
<td>Endemic</td>
<td>Important</td>
<td>Limited</td>
<td>Possible expansion</td>
<td></td>
</tr>
<tr>
<td>Tick-borne African fever</td>
<td>Rickettsia africana</td>
<td>Ticks Amblyomma sp.</td>
<td>Mammals</td>
<td>Sub-Saharan Africa (mainly Southern)</td>
<td>Endemic</td>
<td>High</td>
<td>Mild</td>
<td>None</td>
<td>Possible expansion, better diagnosed</td>
</tr>
<tr>
<td>Rocky Mountain spotted fever</td>
<td>Rickettsia rickettsii</td>
<td>Ticks Dermacentor sp.</td>
<td>Rodents</td>
<td>Northern America</td>
<td>Sporadic</td>
<td>Mild</td>
<td>Important</td>
<td>Yes</td>
<td>Expanding</td>
</tr>
<tr>
<td>Scrub typhus</td>
<td>Orientia tsutsugamushi</td>
<td>Mites Triambicula sp.</td>
<td>Rodents</td>
<td>Far East</td>
<td>Sporadic</td>
<td>Mild</td>
<td>Yes</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>Pestis</td>
<td>Yersinia pestis</td>
<td>Fleas</td>
<td>Rat, Soil</td>
<td>Ubiquitous</td>
<td>Endemically</td>
<td>Low, except in Madagascar and Democratic Republic of the Congo</td>
<td>Important</td>
<td>Yes</td>
<td>Very high if untreated (low with antibiotics)</td>
</tr>
</tbody>
</table>

Table V (continued). – Principal human and zoonotic vector-borne infections, and their epidemiologic characteristics (non-exhaustive list).
<table>
<thead>
<tr>
<th>Diseases</th>
<th>Agents</th>
<th>Vectors</th>
<th>Hosts-reservoirs</th>
<th>Distribution</th>
<th>Mode</th>
<th>Incidence in transmission area</th>
<th>Morbidity</th>
<th>Lethality</th>
<th>Tendency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Protozoans</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td><em>Plasmodium sp.</em></td>
<td>Mosquitoes</td>
<td>Men (and apes?)</td>
<td>Intertropical areas*</td>
<td>Endemo-epidemic</td>
<td>High</td>
<td>Important</td>
<td></td>
<td>High for <em>P. falciparum</em></td>
</tr>
<tr>
<td>Babesiosis</td>
<td><em>Babesia sp.</em></td>
<td>Ticks</td>
<td>Wild mammals</td>
<td>Ubiquitous</td>
<td>Risk for splenectomized people in Europe</td>
<td>Important number of human cases in USA</td>
<td>High in Europe, low in USA</td>
<td>Stable</td>
<td></td>
</tr>
<tr>
<td>Leishmaniosis</td>
<td><em>Leishmania sp.</em></td>
<td>Sand flies</td>
<td>Mammals (including dogs)</td>
<td>All continents, of which Europe, Guyane and Martinique</td>
<td>Endemic</td>
<td>Low</td>
<td>Important</td>
<td></td>
<td>Low for cutaneous form, high for visceral form</td>
</tr>
<tr>
<td>Sleeping sickness 1</td>
<td><em>Trypanosoma brucei rhodesiense</em></td>
<td>Tsetse flies</td>
<td>Wild great ungulates</td>
<td>Eastern Africa</td>
<td>Endemo-epidemic foci</td>
<td>High</td>
<td>Important</td>
<td>Very high if untreated</td>
<td>Expanding</td>
</tr>
<tr>
<td>Sleeping sickness 2</td>
<td><em>Trypanosoma brucei gambiense</em></td>
<td>Tsetse flies</td>
<td>Men (and pigs?)</td>
<td>Western and Central Africa</td>
<td>Endemo-epidemic foci</td>
<td>High</td>
<td>Important</td>
<td>Very high if untreated</td>
<td>Stable</td>
</tr>
<tr>
<td>Chagas disease</td>
<td><em>Trypanosoma cruzi</em></td>
<td>Triatominae</td>
<td>Wild mammals, men</td>
<td>Latin America (including Guyane)</td>
<td>Endemic</td>
<td>Misestimated</td>
<td>Important</td>
<td>Important</td>
<td>Stable</td>
</tr>
<tr>
<td><strong>Metazoa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphatic filariosis</td>
<td>Filariae</td>
<td>Mosquitoes</td>
<td>Men</td>
<td>Africa, Indian Ocean (including Mayotte), Pacific (including French Polynesia, Wallis-et-Futuna), Asia</td>
<td>Endemic</td>
<td>Low</td>
<td>Maybe important and invalidating</td>
<td>None</td>
<td>Diminishing</td>
</tr>
<tr>
<td>Loaiosis</td>
<td><em>Loa loa</em></td>
<td>Horse flies</td>
<td>Men</td>
<td>Central Africa (forest)</td>
<td>Endemic</td>
<td>Low</td>
<td>Important</td>
<td>None</td>
<td>Stable</td>
</tr>
<tr>
<td>Onchocercosis (river blindness)</td>
<td>Filariae</td>
<td><em>Onchocerca volvulus</em></td>
<td>Black flies</td>
<td>Men</td>
<td>Western and Central Africa, Southern America</td>
<td>Endemic</td>
<td>Important</td>
<td>None</td>
<td>Strongly diminishing</td>
</tr>
<tr>
<td>Serous cavity filariosis (Mansonellosis)</td>
<td>Filariae</td>
<td><em>Mansonella sp.</em></td>
<td>Ceratopogonidae</td>
<td>Men</td>
<td>Western and Central Africa, Southern America</td>
<td>Endemic</td>
<td>Important</td>
<td>Low</td>
<td>None</td>
</tr>
</tbody>
</table>

Table V (continued). – Principal human and zoonotic vector-borne infections, and their epidemiologic characteristics (non-exhaustive list).
* Documents of WHO for updated information.
TEXT OF RECOMMENDATIONS

At the individual level, prevention of vector-borne diseases needs a protection strategy against potential vectors, eventually in association with drug and/or vaccine protection. These prevention actions have been particularly studied for malaria and dengue.

GENERAL MEASURES FOR PREVENTION

Recommendation 1
Due to the severity of some vector-borne diseases, analyze the risk and take into consideration measures of personal protection against vectors that would be easiest to apply. The hierarchy of these measures depends on the travel or the stay (place, season, length, modalities), and on the person (age, pregnancy, other pathology).

ROLE OF CUTANEOUS REPELLENTS IN PPAV

In Entomology, the commonly used definition for a repellent is, “a substance that induces an arthropod to leave”. Repellents are classified among the biocides (Directive 98/8/EC) along with insecticides, herbicides and fungicides, which include the main families of pesticides for non-agricultural use.

After the 18th report of the WHO Expert Committee on Malaria (1986), experts recommended that repellents be used as a complement for mosquito nets and insecticide coils to reduce the human-vector contact in an individual protection strategy. In the second report from the WHO Informal Consultation (1996), the role of repellents was well defined, especially against exophagous mosquitoes and sandflies. In the 1990’s, resistance to anti-malaria drugs and insecticides led to an increased use of repellents for cutaneous use or to impregnate clothing for individual protection against vector-borne diseases. The emergence of West-Nile virus in North America led health authorities to review the strategy for protection against mosquito bites. The use of repellents was then highlighted as complementary for behavioral and environmental measures.

Thus, in the context of PPAV, a repellent is a natural or synthetic substance that has a repelling property against hematophagous arthropods. For its activity, it limits human-vector contact. With respect to the potential vector, these repellents can be classified into two categories: plant extracts and synthetic products.

The ten most ideal characteristics of a repellent are:

- long-lasting efficacy on a wide spectrum of arthropods,
- absence of skin irritation,
- lack of cutaneous absorption and toxicity,
- absence of textile fiber alterations during application on clothing,
- absence of fatty residues on the skin,
- confirmed resistance to washing and friction,
- absence of effects on common plastics,
- chemical stability,
- reasonable price for a wide use, and
- pleasant scent or lack of smell.

The use of a cutaneous repellent in PPAV has become an essential strategy to hinder arthropod biting and to fight vector-borne disease such as malaria, dengue, filariasis, etc... Repellents do not generally kill arthropods but modify their olfactory perception of their host. While DEET (N,N-diethyl-meta-toluamide) has led the repellent market since 1946, new molecules have appeared in the recent years and improved this mode of protection because their smell is less pronounced, their texture is perceived better and they exhibit a general tolerance. Repelling molecules now in the approval process in Europe for the European Biocide Products Directive 98/8/EC are: DEET, picaridin\(^8\) (1-piperidin carboxylic acid, 2(2-hydroxyethyl)-methylpyrolester), IR3535\(^9\) [3-(N-acetyl-N-butylaminopropionic acid ethyl ester] and PMDRO\(^10\) (mixture of cis- and trans-para-menthan-3,8-diol) formerly known as Citriodiol\(^TM\). Application of these products must follow some rules.

The interest in essential oils extracted from plants, as insecticides and as a potential repellent is currently expanding. Thus, a large number of extracts are studied in laboratories; however, they are complex mixtures of terpenic and aromatic derivates that vary greatly depending of the geographic area of the plant used, the manufacturer and each batch. As these extracts are very volatile, they are often used with vanillin to increase their repelling activity; this additional effect may be due to the synergy between several related molecules. The active pharmaceutical ingredients are not devoid of adverse effects, for instance citral can cause a cutaneous rash and eugenol has carcinogenic effects. Their use must be restricted to individual protection against arthropods. Two molecules were synthesized from essential oils and used for a PPAV:

1. permethrin, a synthetic pyrethrin derived from the chrysanthemum species, *Chrysanthemum* or *Tanaacetum cinerariifolium*, is reserved for impregnation of clothing and mosquito nets. It exhibits both insecticidal and repellent activities;
2. Citriodiol\(^TM\) (PMDRO), derived from the eucalyptus *Corymbia citriodora* is used as skin repellent.

The benefit of using repellents against biting, hematophagous, disease-transmitting vectors override the risks without harming their texture is perceived better and they exhibit a general tolerance. Repelling molecules now in the approval process in Europe for the European Biocide Products Directive 98/8/EC are: DEET, picaridin\(^8\) (1-piperidin carboxylic acid, 2(2-hydroxyethyl)-methylpyrolester), IR3535\(^9\) [3-(N-acetyl-N-butylaminopropionic acid ethyl ester] and PMDRO\(^10\) (mixture of cis- and trans-para-menthan-3,8-diol) formerly known as Citriodiol\(^TM\). Application of these products must follow some rules.

The interest in essential oils extracted from plants, as insecticides and as a potential repellent is currently expanding. Thus, a large number of extracts are studied in laboratories; however, they are complex mixtures of terpenic and aromatic derivates that vary greatly depending of the geographic area of the plant used, the manufacturer and each batch. As these extracts are very volatile, they are often used with vanillin to increase their repelling activity; this additional effect may be due to the synergy between several related molecules. The active pharmaceutical ingredients are not devoid of adverse effects, for instance citral can cause a cutaneous rash and eugenol has carcinogenic effects. Their use must be restricted to individual protection against arthropods. Two molecules were synthesized from essential oils and used for a PPAV:

1. permethrin, a synthetic pyrethrin derived from the chrysanthemum species, *Chrysanthemum* or *Tanaacetum cinerariifolium*, is reserved for impregnation of clothing and mosquito nets. It exhibits both insecticidal and repellent activities;
2. Citriodiol\(^TM\) (PMDRO), derived from the eucalyptus *Corymbia citriodora* is used as skin repellent.

The benefit of using repellents against biting, hematophagous, disease-transmitting vectors override the risks...
of the potential severity of the transmitted diseases at all ages. The recommendation for repellent use must also be accompanied by the following measures:

1. Adapt the application frequency to the principal human and vector activities present in the visited or inhabited geographic area;
2. Apply on healthy, uncovered skin (useless underneath clothes);
3. Do not spray directly on the face due to proven risk of eye irritation, instead spray hands and then apply onto the face, avoiding contact with peri-mucous and ocular areas;
4. Rinse skin before sleep to avoid irritation by mace ration in skinfolds;
5. The repellent must be applied on children by adults.

**Recommendation 2**

Only use skin repellents where the active ingredient has been evaluated as innocuous (low toxicity to animals and humans, genotoxicity, ecotoxicity) but efficient with respect to European regulation on biocidal products (Directive 98/8/EC). Follow the recommendations regarding their use. Active ingredients currently being evaluated and contained in biocidal products are: DEET, picaridin (icaridin or KBR3023), IR3535, and PMDRBO (Citriodiol™). Eventually, commercial formulas will be submitted in Europe for drug approval processes.

**Recommendation 3**

To protect from *Anopheles* during a stay in a malaria endemic area, use a commercial formulation where the active ingredient concentration is substantial enough to ensure efficient protection during at least 4 hours in field conditions, with regards to following data (Grade A).

For each product, efficient concentrations are:
- DEET: 30-50 %
- IR3535: 20-35 %
- Picaridin: 20-30 %
- PMDRBO: 20-30 %

At these concentrations, the efficiency has been shown for a longer period for *Aedes* and *Culex* species. The modalities of use must be adapted to the age and physiological conditions for each individual (child, pregnant women: see following recommendations).

**Recommendation 4**

Do not use essential oils as skin repellents because they generally have an efficacy of less than 20 minutes for principal vectors, are photo sensitive, and have high risk for allergy development (Grade B).

**Recommendation 5**

Do not apply skin repellents and sun protections at the same time. The repellent should be applied only 20 minutes after the sun protection (Grade B).

About recommendation 5, the workgroup reminds the importance of physical measures for sun protection (i.e. hat, protective clothing).

The workgroup proposes that:

1. The terminology used by industry to qualify finished products should be regulated. For instance:
   a. A product stating a use in tropical areas should have undergone stability studies under tropical conditions and efficiency determined in the field; laboratory studies should comprise, in addition to evaluation for *Culex* and *Aedes* species, assays with one vector *Anopheles* species.
   b. A product stating a use in temperate areas should have undergone efficiency studies against ticks in addition to *Culex* species.
2. Mixed products containing both repellents and sun protectents should not be available for purchase.

**Role of Impregnated Mosquito Nets in PPAV**

The use of mosquito bed nets is very old and corresponds to a simple mechanical protection that efficiently limits human-vector contact, provided that it is intact and well set. Impregnation of mosquito nets by a synthesized pyrethroid has demonstrated its efficacy on the decreasing the incidence of malaria at both individual and collective scales.

Impregnated mosquito nets have four recognized purposes:

1. Dissuasive effect: Less mosquitoes enter the dwelling;
2. Excito-repellent effect: mosquitoes leave more rapidly from the dwelling;
3. Inhibitory effect on feeding obtained by disturbing mosquito behavior;
4. Lethal and fast “knock down” (KD) effect.

However, with the extensive use of pyrethroids especially in agriculture, are resulting in an emerging:

1. Progressive mosquito selection towards pyrethroid tolerance, which is leading to a weak KD effect.
2. Behavioral changes of the mosquitoes.

Mosquito nets provide effective protection against many vectors with nocturnal activity. Some studies show efficiency against Chagas disease and leishmaniosis, however, few studies have looked at the efficiency for travelers.
**Recommendation 6**  
**a** – Travelers and residents should use impregnated mosquito nets to prevent malaria. The use of mosquito nets over beds should be the preferred PPAV measure for children before walking age (Grade A).  
**b** – Mosquito nets with industrial, long-lasting impregnation are preferred. However, mosquito nets conventionally or user impregnated with commercially available kits can be used as long as the validated precautions of use are taken into consideration (Grade A).  
**c** – Perform manual impregnation methods in well-ventilated spaces to avoid possible lung or eye irritation.

**Recommendation 7**  
**a** – Travelers and residents should use impregnated mosquito nets to prevent other vector-borne diseases, in particular arboviroses, Chagas disease and leishmaniosis (Grade B).  
**b** – The use of mosquito nets over beds should be the preferred PPAV measure for children before walking age.

**Recommendation 8**  
Tour operators should indicate in their catalogues or leaflets the presence/absence of mosquito nets in the hosting structures. The workgroup also suggests that a follow-up card be made available for the customer (indicating the substance used and the validity date for impregnation).

**ROLE OF IMPREGNATED CLOTHES AND FABRICS IN PPAV**

The first synthetic repellents appeared during the Second World War and have been used for fabric impregnation. Since then, numerous technical advances have been made for repellent or insecticide molecules, fabrics and their treatment, while arthropod susceptibility to biocides have evolved. The persistence of impregnated fabric efficiency depends on numerous elements that affect the bioavailability and the persistence of the insecticide, and include:  
- a. type of fabric,  
- b. treatments applied,  
- c. active ingredient formula,  
- d. type of impregnation,  
- e. washing method and f. UV exposure. In addition, the level of arthropod susceptibility also affects the product efficiency.

Six impregnated fabrics or supports were identified after a bibliography analysis. They are cited thereafter listed according to an increasing level of contact with skin:  
1. Paper or plastic strips from Sumitomo Chemical Ltd (Osaka, Japan), which are impregnated with metofluthrin (still under study);  
2. Polyethylene tarpaulin, impregnated during their production with deltamethrin;  
3. Tents impregnated with insecticides, primarily pyrethroids;  
4. Curtains impregnated with pyrethroids;  
5. Blankets, sheets or fabrics impregnated with permethrin;  
6. Impregnated clothing.

**Recommendation 9**  
Wear loose and long-sleeved/legged clothes to protect against vector bites.

**Recommendation 10**  
**a** – Servicemen, foresters (Grade B), hunters, fishermen (Grade C) and also travelers should use clothing impregnated with permethrin, preferring clothes pre-impregnated during their production.  
**b** – Impregnated clothes must be combined with a skin repellent used on exposed parts of the body (Grade B) and should never replace an impregnated mosquito net while sleeping.  
**c** – Be aware of the duration of impregnation efficiency and its resistance to washing, which is low in case of manual impregnation.  
**d** – Companies that propose impregnated clothing and fabrics should indicate arthropods targeted and the duration of impregnation efficiency.

**Recommendation 11**  
Residents should mount curtains impregnated with pyrethrinoids in addition to impregnated mosquito nets or when mosquito nets are not available (Grade B). Recommendation 11 also applies to tourist resorts.

**Recommendation 12**  
When no other means (mosquito nets or mosquito net-hammocks) are available, use:  
- For travelers in extreme conditions or for temporary camping, polyethylene tarpaulins impregnated during their production with concentrations ≥ 360 mg deltamethrin per square meter or tents impregnated with permethrin with a concentration of 1,000 mg/m² for an inner tent and protected by a double roof, or 2,000 mg/m² for a simple-roofed tent (Grade B).  
- For nomadic populations, a sheet, fabric pieces or blankets impregnated with permethrin at a concentration of 1,000 mg/m² (Grade B). Re-impregnation should be performed according to precautions of use, with validated kits that are commercially available.
**ADDITIONAL MEASURES IN PPAV**

Commercialized insecticides in France are synthesized pyrethrinoids or carbamates, principally designed for controlling harmful insects, and possess an immediate lethal effect with variable persistence on arthropods. Dispensed volumes during spraying with an atomizer or during passive diffusion are never standardized and always unknown by the user. A traveler, and in particular an expatriate, who wishes to buy room insecticides (in particular atomizers) is often restricted to purchase them on-site. The efficiency of local products is not guaranteed and even less is known about their innocuousness. Normal product control can vary greatly from one country to another.

Performed studies highlighted that:

1. The number of synthetic products or natural insecticides available for the general public is very important;
2. The general public does not have sufficient knowledge to use these products appropriately;
3. Instructions dedicated to the general public provide weak, wrong or undocumented suggestions regarding insects targeted, which can elicit side effects for the user and others, and/or the environment;
4. No instructions (even for so-called “natural” or “organic” insecticides) specify that “suppressing the larva nests” is a cheap (often free), efficient and ecological method (i.e. by eliminating standing waters around houses for mosquitoes, by vacuuming for fleas);
5. Insects targeted often have various labels on packaging, which allow the customer to understand in different manners the following terminologies: “all insects”, “harmful-flying-crawling insects”, “mosquitoes”, “special tiger mosquito”, “cockroaches”, “fleas”, “bugs”, “mites”, “special allergenic mites”, etc...
6. According to present knowledge, the placement of light traps cannot be specified;
7. Combustion of smoke coils releases numerous substances. Prolonged exposure to these substances are linked with some lung cancers. A recent study performed by the French AFSSET underlined the risk of unsuitable health effects due to smoke released by these coils, particularly during chronic exposure. Consequently, except during epidemics, other means are preferred especially for children, elders, asthmatics and people with respiratory disorders.

The workgroup recommends:

**Recommendation 13**
Do not “blind use” insecticides against unknown arthropods. Insecticidal control must be adapted to one or several identified arthropods.

**Recommendation 14**
Perform mechanical measures for control (destruction of larva nests, mounting of mosquito nets on windows and doors) concomitantly or before the use of chemical insecticides.

**Recommendation 15**
It is possible to use the following insecticides (though they must remain only additional measures in PPAV): atomizers for occasional use, insecticides with continuous diffusion (heating electric plugs) or in a liquid state (indoor use) (Grade B). Smoke coils must be reserved for short durations and outdoor use.

To be efficient, air-conditioning needs a good management of openings, since they constitute a limiting effect on the entrance of insects. In tropical areas, the temperatures reached (20 to 25 °C) are still compatible with vector survival and activity. Moreover, ventilation disturbs the flight of mosquitoes, which can take refuge in corners and then resume their activity once it is switched off (with or without air-conditioning). Air-conditioning and ventilation can be complemented by the use of an indoor diffusible insecticide, provided electricity supplying is continuous. Other means for personal protection are available in stores, but their efficiency has not been proved (recommendations 17 and 18).

**Recommendation 16**
Do not use air-conditioning and ventilation as the only means for PPAV. They must be complemented by airtightness of the places and by the use of insecticides to reduce the man-vector contact indoors (Grade C).

**Recommendation 17**
Do not use anti-insect wristbands to protect from mosquitoes and ticks (Grade A).

**Recommendation 18**
Do not use an ultrasound device, vitamin B1 (Grade A), homeopathy, electric swatters, glue ribbons, papers and stickers without insecticides.

**CONSIDERATION OF PARTICULAR FIELDS FOR PPAV**

Particular fields: in the literature only studies about pregnant women, children and, to a lesser extent, lactating women can be found. There are no data about elderly or obese people. For newborns, infants and
children, vectors, transmitted pathogens and diseases that concern PPAV are the same as for adults. Pharmacological data recommend the use of repellents for children from 3 months, when the risk of severe vector-borne disease is confirmed. For safety reasons, it is proposed not to start the use of repellents before the age of 6 months; other PPAV measures should be preferred (i.e. impregnated mosquito nets).

For pregnant women, a study concerning the use of DEET at a 20% concentration did not provide specific maternal-fetal risks (proof level 1). Toxicological data on reproduction, clinical data and/or experience did not provide evidence that repellents were harmful during pregnancy. Pregnant women should follow the same recommendations as other adults (see recommendation 3). Length of time spent in areas subjected to transmission of vector-borne diseases should lead to a specific benefit-risk evaluation for pregnant women.

The absence of data in the literature about the use of PPAV in people with dermatitis does not allow for the identification of a secondary dermatological risk comparison to people without such lesions. Chronic, dry lesions of the skin are not a contraindication to the use of repellents.

**Recommendation 19**

a – Pregnant women should use impregnated mosquito nets, prefer physical means for protection and limit exposure time to vectors, in particular at dawn and at night (Grade A).

b – As toxicological data on reproduction, clinical data and/or experience did not highlight risks, pregnant women can use repellents at any stage of pregnancy when the risk of severe, vector-borne disease transmission is high. In this context, particular attention will be given to giving the lowest efficient concentration of the active ingredient. As a reminder, 4-hour efficiency against Anopheles in field conditions is reached with the following concentrations: DEET: 30%, picaridin: 20%, IR3535: 20%, PMDRBO: 20%.

c – The use of repellents by lactating women is recommended, respecting the same precautions of use as for any adult, avoiding the breast and washing hands before lactation.

**Recommendation 20**

Children from the age of 6 months can be subjected to application of skin repellents in areas at risk for transmission of severe, vector-borne diseases.

<table>
<thead>
<tr>
<th>Age</th>
<th>Max applications per day</th>
<th>DEET*</th>
<th>Picaridin</th>
<th>PMDRBO IR3535*</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months-walking age</td>
<td>1</td>
<td>10-30%</td>
<td>-</td>
<td>20-30%</td>
</tr>
<tr>
<td>Walking age-24 months</td>
<td>2</td>
<td>10-30%</td>
<td>-</td>
<td>20-30%</td>
</tr>
<tr>
<td>24 months-12 years</td>
<td>2</td>
<td>20-30%</td>
<td>20-30%</td>
<td>20-30%</td>
</tr>
<tr>
<td>&gt; 12 years</td>
<td>3</td>
<td>20-50%</td>
<td>20-30%</td>
<td>20-30%</td>
</tr>
</tbody>
</table>

* In case of exposure to anopheles vectors of Plasmodium, agents of malaria, the minimum efficient concentration of DEET is 30%.

Toxicological data, clinical data and/or experience did not yet provide evidence against use in children, except in case of misuse; therefore it is recommended to use skin repellents in children from the age of 6 months in case of elevated risk from transmission of severe vector-borne diseases. In this case, the use of the minimum efficient concentration for the targeted vector must be carefully respected, as well as the maximum number of daily applications regarding the age.

1. *DEET has been subjected to an assessment at the European level, usage restriction was pronounced for children before 12 years of age. However, in case of elevated risk for transmission of vector-borne disease, it can be used for a short period carefully respecting the maximum number of applications and the practical usage conditions in children.*

2. *Only France emitted usage restriction for IR3535 in children before the age of 30 months. This position will probably be revised according to the European assessment.*

Picaridin, PMDRBO and IR3535 are currently being assessed at the European level.

**Recommendation 21**

For children, respect the following precautions:

a – Limit exposure time to vectors, particularly at dawn and dusk;

b – Preferentially choose physical means for protection (mosquito bed nets (Grade A), or loose and impregnated protecting clothing);

c – Place room insecticide dispensers away from the beds of newborns or infants;

d – Prevent ingestion or projections into the eyes by keeping atomizers away from children and prevent application and manipulation of repellents and insecticides by children (Grade B);

---

11 Cutaneous absorption is more important before 3 months, absorbed doses/body surface ratio is higher, distribution of liposoluble substances to the central nervous system (CNS) is greater in children because of lower fat tissue quantity, blood-brain barrier is functional from birth, liver enzymes are matured from 6-month age and glomerular filtration is carried out from the age of 1 to 6 months.
Recommendation 22
In case of extended skin lesions, use impregnated clothing (depending on the vector risk). In case of application of repellents on localized skin lesions, carefully wash repellents away, particularly DEET, as soon as the exposure to vector is over.

Recommendation 23
a – People with lung disorders, in particular asthma, should not use smoke coils, nor repellent or insecticide spraying and instead should use insecticide dispensers, depending on their tolerance (Grade B).
b – Additionally, they should prefer pre-impregnated fabrics (clothing and mosquito nets) and not manipulate permethrin.

Recommendation 24
People with contact lens should not handle their lenses after application of repellents due to the risks of irritation and eventual alteration of the contact lenses, in particular by DEET (Grade A).

Acceptable risks associated to the use of a PPAV
Data in the literature does not identify a simple and unique indicator for the transmission capacity of the different vector-pathogenic agents. Transmission potential depends on numerous factors that entomologists group into the categories “vectorial competence” and “vectorial capacity”. Vectorial competence is the intrinsic property of a vector population to transmit a population of pathogens, as evidenced in laboratories. Vectorial capacity results from the conjugation of vectorial competence and environmental conditions: it is evaluated in the field for a chosen vector population under specific conditions. The principal of vector-pathogenic agents are well defined (see table 5), as well as vectorial competence, but the importance of the transmission of a pathogen by a vector is strongly heterogeneous due to numerous factors in relation with the host, the vectors, the pathogens and the environment. Travelers and healthcare providers must consider whether the unsuitable effects eventually linked to PPAV are acceptable when compared to vectorial risk. For each case, the benefit-risk balance needs to be evaluated, though few direct elements are available in the literature. The workgroup has listed the relevant data about documented severe toxicity of products used in PPAV and the principal data about epidemiology, morbidity and severity of pathologies during vector-borne transmission.

According to literature:
- Acute toxicity of pyrethrinoids in normal use for PPAV is very limited and there is no evidence about long-term toxicity;
- Unsuitable, severe systemic effects of skin repellents are rare and often due to misuse. Almost all unsuitable effects of DEET, the oldest and most studied, are related to irritation of skin, mucosa, and the central nervous system.

Recommendation 25
The “disease” risk should be considered as superior to the “toxicity” risk of the repellents and/or insecticides when they are used following the prescribed rules.

Recommendation 26
During epidemics, PPAV measures should be reinforced for both residents and visitors. These measures can also lower the risk of establishing an infection in non-endemic areas for transmission of vector-borne diseases.
In malaria endemic areas, these measures must also be reinforced, particularly in the absence of prophylaxis.
In French regions particularly exposed, the workgroup suggests that the health authorities monitor exposure of residents (volumes of products consumed, analytic exposure controls).

Long-term deleterious effects of PPAV measures
The environmental impact of the use of repellents and insecticides for PPAV has been poorly studied so far. However, ecotoxicology will be considered for all biocides in the framework of the Directive 98/8/EC, as well as the impact on health by bioaccumulation.

Environmental impacts can be defined as:
- Non-specific that result from the materials used for fabrication and the environmental cost. Such impacts are high for “technological” solutions, which are mostly recognized as inefficient (see R17 and R18). The products are generally manufactured overseas (environmental cost due to transportation) and made of plastics, which constitute difficult waste management.
- **Specific** impacts that are linked to the insecticidal and/or repellent molecules that are used.

Numerous publications link the health risks to the general use of pesticides mostly in agriculture but also for vector control, but the risks to health under prolonged, repeated, and regular exposures to products used for PPAV were not taken into account.

**Recommendation 27**

All products used for PPAV should:

a – Have undergone efficiency and ecotoxicology studies;
b – Not be discarded into nature after use or in case of surplus (as for the case of the re-impregnation products).

**Risks for Human Health**

**In Relation with Harms and Protection Means**

Besides arthropods that are vectors of pathogens, some other arthropods are pathogenic by themselves (harms due to stings or bites, myiasis, etc...) or serve as intermediary hosts. As a reminder, fatality due to a wasp sting is higher than due to snake bites in Metropolitan France.

The principal harms are usually caused by the following groups of arthropods:

1) **Class: Insecta**

a – Order: Hymenoptera (*i.e.* bees, wasps, hornets, ants), which cause dermatological manifestations ranging from local to systemic reactions, eventually lethal.

b – Order: Diptera, containing:

- hematophagous species (*i.e.* mosquitoes, flies, horseflies, gnats), which lead to various dermatological reactions such as papular urticaria, localized regional edema, etc...

- myiases agents, which are flies whose larvae develop within tissues, natural cavities or wounds. One can distinguish furuncular, migrating, wound and cavity myiases.

c – Order: Anoplura (sucking lice), which cause various dermatological manifestations ranging from itching to excoriation, impetiginization, etc...

d – Order: Psocoptera (booklice, barklice.), which causes dermatitis and respiratory allergies.

e – Order: Siphonaptera, which are hematophagous fleas that provoke papular urticaria localized to lower limbs or that are diffuse, and chigoe fleas (*a.k.a.* jiggers) whose females burrow into the skin, leading to tumefactions in the tegument and the formation of a black furuncular nodule surrounded by a white halo.

f – Order: Hemiptera:

- hematophagous species (*bedbugs, Triatoma sp.*), whose dermatological manifestations are principally edematous papules or localized urticaria.

- non-hematophagous species (typical bugs), whose bites lead to a superficial burning-type vesicating effect.

g – Order: Lepideroptera (*butterflies*); the scales of some adults or the hair of some caterpillars can provoke painful, edematous erythema, which can sometimes be bullous. An ocular topography is often observed (palpebral edema, conjunctivitis and keratitis) and some rare clinical outcomes can occur (itch and/or generalized exanthema, dyspnea, shock, disseminate intravascular coagulation).

h – Order: Coleoptera, whose dermatological manifestations range from vesicular-bullous eruptions (*Cantharidae*) to superficial burning-typed dermatitides (*Staphylinidae*).

One of the main dermatological manifestations after an arthropod bite (insects or mites) is papular urticaria, whose clinical descriptions are as follows:

- Erythematous, edematous papules from 3 to 10 mm diameter, pruriginous, sometimes accompanied by a rapidly excoriated vesicle, usually in plaques, with an irregular disposition although classically symmetrical. Duration: 2 to 10 days. Evolution to prurigo or pigmented lesion.

- Topography: usually on unprotected areas like the limbs (with some arthropods, protected areas and zones of cloth tightening). Number: a few elements to several tens.

2) **Class: Arachnida**

a – Order: Araneae (*spiders*); the bites of some species can trigger severe dermatological manifestations (large-sized ulcers) and systemic signs.

b – Order: Scorpiones (*scorpions*), whose bites can trigger an immediate and sometimes an intolerable burning, numbness of the region possibly accompanied by lymphangitis and adenitis. Toxin (neurotoxin) syndromes are observed in some species.

c – Order: Acarina:

- Itch mites provoke a diffuse prurit, pruriginous papules with a frequent eczema and impetigis.

- Harvest mites (numerous species) trigger the formation of highly pruriginous papules or erythematous papulovesicles.

- Ticks, whose bites can lead to dermatological syndromes varying from acute syndrome (hardened erythematous plaques, necrotic ulcers, bruised lesions, bullo-pustular plaques) sometimes accompanied of secondary infections, to a chronic syndrome (*granu-“
lomatous plaque or nodule that can persist several years). Some pathogens that are transmitted by ticks can also generate pathologies with cutaneous symptoms, such as erythema migrans (Lyme disease) or eschars accompanied by regional adenopathies or lymphangitides (spotted fever-type rickettsiosis).

3) Class: Myriapoda

a – Order: Chilopoda (centipedes); the bites of certain species can provoke a painful erythema with possible ulceration.

b – Order: Diplopoda (millipedes); contact with some species can lead to vesicating lesions (superficial burns, blisters) and/or periorbital edema (conjunctivitis, keratitis).

Recommendation 28

The most frequent pathology observed after a journey in tropical areas is a superinfection caused by scratching lesions due to arthropod bites, in particular these of mosquitoes. Repellents have been tested alone or in association and at various concentrations, against some other harming arthropods than Culicidae: Reduviidae, Ceratopogonidae, Phlebotominae, Pediculicidae and ticks. Protection sometimes lasts more than 6 hours, but these assays must be standardized to allow a better comparison of the results and a better evaluation of their real efficiency. To avoid known harms:

a – wear protective clothing, which can constitute a physical barrier (eventually impregnated);

b – sleep under a mosquito net, if possible impregnated (Grade B);

c – and, if these methods are insufficient or not adapted to circumstances, use an insecticide or skin repellents, if their efficiency was demonstrated against the harming arthropod and respecting the usage recommendations (Grade A).

Currently available repellents are not efficient for a protection against hymenoptera stings (Grade B).

Recommendation 29

For prevention of malaria, PPAV is inseparable from chemoprophylaxis recommended by health authorities (Grade A).

Recommendation 30

Protection against yellow fever, Japanese encephalitis and tick-borne encephalitis is based on vaccination. In case of contraindication to vaccination, absence of vaccination and if the travel cannot be delayed, use PPAV measures (Grade C). PPAV must then be the object of a written prescription.

Recommendation 31

Due to poor knowledge of travelers and residents, they should be informed about vector-borne diseases and about protection methods during vaccination or medical visits before departure. Thus, to choose the optimal PPAV measures, use the two following decision-making diagrams, preferring simple messages in order to optimize the application (Decision-making diagrams 1-A et 1-B) (Grade C).

The following decision-making diagrams help orientate towards the choice of PPAV methods. During epidemics or during periods of maximal transmission, travelers, residents and expatriates should be informed about the measures in the shaded cells in Diagrams 1-A and 1-B.

Whatever the duration, itinerant tourism is classified as short stay, because the traveler will face various situations in areas with diverse epidemiological characteristics.
PERSONAL PROTECTION AGAINST BITING INSECTS AND TICKS

Recommendations for good practice

Parasite, 2011, 18, 93-111

REFERENCES

The list of bibliographic references and documents used to write this review and make these recommendations can be obtained sending a message to one of the corresponding authors.

ACKNOWLEDGEMENTS

This work has been funded by the “Direction Générale de la Santé”, the “Société de Médecine des Voyages” and the "Société Française de Parasitologie". All the colleagues who have participated in the preparation of this document and the partner Societies and Institutions (Société de Pathologie Exotique, Société de Pathologie Infectieuse de Langue Française, Collège des Universitaires de Maladies Infectieuses et Tropicales, Société Française de Dermatologie, Groupe de Pédiatrie Tropicale de la Société française de Pédiatrie, Société de Formations Thérapeutiques du Généraliste, Société Française de Médecine des Armées, Institut de Recherche pour le Développement, Service de Santé des Armées, Centre de Référence des Agents Tératogènes, Confédération du Logement et du Cadre de Vie) are thanked. Special thanks to Vivactis Plus (Ms Nathalie Pasquier-Desvignes) for the organization of the meetings and the coordination of the work.


+++ Essential; ++: Very important; +: Important; *: Complementary; * Whenever impregnated mosquito nets are not available, use non-impregnated ones; § Out of an epidemic context of vector mosquito control, one should prefer other protection means than smoke coils, above all in children, elders, asthmatics and other respiratory disorders.

Decision-making diagram 1-B. – Diurnal transmission (dengue, yellow fever, Chikungunya, sleeping sickness).

+++ Essential; ++: Very important; +: Important; *: Complementary; * Whenever impregnated mosquito nets are not available, use non-impregnated ones; ‡ Preferentially used for tick-borne diseases; § Out of an epidemic context of vector mosquito control, one should prefer other protection means than smoke coils, above all in children, elders, asthmatics and other respiratory disorders.

<table>
<thead>
<tr>
<th>Short or itinerant trip</th>
<th>Long and fixed stay (resident, expatriate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impregnated mosquito net* (++++)</td>
<td>Impregnated mosquito net* (+) Ventilation/air-conditioning (+)</td>
</tr>
<tr>
<td>OR ventilation/air-conditioning (+) AND use of a diffusible indoor insecticide (++)</td>
<td>OR ventilation/air-conditioning (+) AND use of a diffusible insecticide indoors (+)</td>
</tr>
<tr>
<td>OR window and door mosquito nets (++)</td>
<td></td>
</tr>
<tr>
<td>Protecting clothes, ideally impregnated (++)</td>
<td>Intradomiciliar spraying of remnant insecticides (+++)</td>
</tr>
<tr>
<td>Skin repellents on exposed areas (++)</td>
<td>Window and door mosquito nets (++)</td>
</tr>
<tr>
<td>Smoke coils§ outdoors (+)</td>
<td>Impregnated clothes (++)</td>
</tr>
<tr>
<td>Baby-bed, pushchair (...) mosquito net* for a child under walking age (++++)</td>
<td>Skin repellents when outdoors (++)</td>
</tr>
<tr>
<td>Impregnated protecting clothes ‡ (++)</td>
<td>Smoke coils§ outdoors (+)</td>
</tr>
<tr>
<td>Skin repellents ‡ (++)</td>
<td></td>
</tr>
<tr>
<td>Electric insecticide dispenser (indoors) (++)</td>
<td>Electric insecticide dispenser (indoor) (++)</td>
</tr>
<tr>
<td>Window and door mosquito nets (++)</td>
<td>Peridomiciliar control of larva nests (++)</td>
</tr>
<tr>
<td>Air-conditioning (+) OR impregnated mosquito net* (+) especially in epidemic situation (++)</td>
<td>Impregnated mosquito net* (+)</td>
</tr>
<tr>
<td>Smoke coils§ outdoors (+)</td>
<td>Skin repellents (++)</td>
</tr>
<tr>
<td></td>
<td>Smoke coils§ outdoors (+)</td>
</tr>
</tbody>
</table>
RECOMMENDATIONS FOR GOOD PRACTICE

PERSONAL PROTECTION AGAINST VECTORS

or PROTECTION AGAINST BITING INSECTS AND TICKS

organised by

the Société de Médecine des Voyages (SMV)

and

the Société Française de Parasitologie (SFP)

with the participation of the following Learned Societies:

Société de Pathologie Exotique (SPE)

Société Pathologie Infectieuse de Langue Française (SPLIF)

Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT)

Société Française de Dermatologie (SFD)

Groupe de Pédiatrie Tropicale de la Société française de Pédiatrie (GPT)

Société de Formation Thérapeutique du Généraliste (SFTG)

Société Française de Médecine des Armées (SFMA)

and

Institut de Recherche pour le Développement (IRD)

Service de Santé des Armées (SSA)

Centre de Référence des Agents Tératogènes (CRAT)

Confédération du Logement et du Cadre de Vie (CLCV)

ORGANIZING COMMITTEE

Fabrice LEGROS
CNR du Paludisme, Paris

Thierry ANCELLE – thierry.ancelle@cch.aphp.fr
Parasitologist, epidemiologist, Paris

Éric CAUMES – eric.caumes@psl.ap-hop-paris.fr
Infectiologist, Paris

Marie-Laure DARDÉ – darde@unilim.fr
Parasitologist, Limoges

Jean DELMONT – jean.delmont@ap-hm.fr
Tropical doctor, Marseille

Robert DESCLOITRES – rdescloitres@free.fr
Representing of the CLCV, La Rochelle

Patrick IMBERT – patrick.imbert@santarm.fr
Pediatra, Saint-Mandé

Ludovic DE GENTILE – LuDeGentile@chu-angers.fr
Parasitologist, Angers

René MIGLIANI – rene.migliani@santarm.fr
Medical epidemiologist, Saint-Mandé

Patrick OUVRARD – patrick.ouvrard@mac.com
General practitioner, Angers

Vincent ROBERT – vincent.robert@ird.fr
Medical entomologist, Montpellier

WORKGROUP

Coordinator Gérard DUVALLET
gerard.duvallet@univ-montp3.fr or gerard.duvallet@cefe.cnrs.fr
Medical entomologist, parasitologist, Montpellier

Nathalie BOULANGER – nboulanger@unistra.fr
Parasitologist, pharmacist, Illkirch

Fabrice CHANDRE – fabrice.chandre@ird.fr
Medical entomologist, Montpellier

Nathalie COLIN DE VERDIERE – nathalie.colin-de-verdier@sls.aphp.fr
Infectiologist, Paris

Paul-Henri CONSIGNY – consigny@pasteur.fr
Infectiologist, Paris

Pascal DELAUNAY – delaunay.p@chu-nice.fr
Medical entomologist, parasitologist, Nice

Jérôme DEPAQUIT – jerome.depaquit@univ-reims.fr
Parasitologist, medical entomologist, Reims

Barbara DOUDIER – bdoudier@hospitai-saint-joseph.fr
Infectiologist, Marseille
PERSONAL PROTECTION AGAINST BITING INSECTS AND TICKS

Recommendations for good practice

Parasite, 2011, 18, 93-111

Michel Franc – m.franc@envt.fr
Veterinary parasitologist, Toulouse

Florence Moulin – florence.moulin@svp.aphp.fr
Pediatra, Paris

Frédéric P佳es – imtssa.entomo@wanadoo.fr
Medical entomologist, epidemiologist, Marseille

Aurélie Prangé – sv.poieters@orange.fr
Veterinary, Poitiers

Isabelle Quatreoss – iquatreoss@hotmail.com
Polyvalent medecine, epidemiologist, Elbeuf

Vincent Robert – vincent.robert@ird.fr
Medical entomologist, Montpellier

Philippe Saviu – PSaviuc@chu-grenoble.fr
Toxicologist, Grenoble

EXTERNAL EXPERTS CONSULTED FOR THE WORKGROUP

Stéphane Auvin – auvin@invivo.edu
Neurologist pediatra, Paris

Francis Carsuzza – francis.carsuzza@wanadoo.fr
Dermatologist, Toulon

Amandine Cochett – a.cochet@invs.sante.fr
Epidemiologist, Saint-Maurice

Frédéric Darriet – frederic.darriet@ird.fr
Medical entomologist, Montpellier

Anne Demantke – agenin-demantke@vinci.com
Occupational medecine, Rueil-Malmaison

Élisabeth Elefant – elisabeth.elefant@trs.aphp.fr
Medical biologist, Paris

Anna-Bella Failoux – afailoux@pasteur.fr
Medical entomologist, Paris

Ludovic de Gentile – LuDeGentile@chu-angers.fr
Parasitologist, Angers

Christophe Lagneau – clagneau@eidl-med.org
Research and development director, EID Méditerranée, Montpellier

Guy La Ruche – g.lauche@invs.sante.fr
Medical epidemiologist, Saint-Maurice

Catherine Pecquet – catherine.pecquet@tmn.aphp.fr
Dermatologist, Paris

Frédéric Sorge – freedso@gmail.com
Pediatra, Paris

Arnaud Tarantola – a.tarantola@invs.sante.fr
Medical epidemiologist, Saint-Maurice

Catherine Vauzelle – catherine.vauzelle@trs.aphp.fr
General practitioner, Paris

READING GROUP

Faiza Ajana – fajana@ch-tourcoing.fr
Infectiologist, Tourcoing

Alexis Armengaud – alexis.armengaud@ars.sante.fr
Medical epidemiologist, public health, Marseille

Jean-Paul Boutin – jevpaul.boutin@free.fr
Medical epidemiologist, Marseille

Sandrine Chevailler – sandrine.chevailler@mairie-valence.fr
Public health nurse, Valence

Suzanne Gagnon – suzanne.gagnon@ssss.gouv.qc.ca
Family doctor, Québec, Canada

Sabine Genty – sgenty@technip.com
Medical doctor, travel consultations, Bobigny

Romain Girod – rgirod@pasteur-cayenne.fr
Medical entomologist, Cayenne, Guyane Française

Nadine Godineau – nadine.godineau@gmail.com
Parasitologist, International vaccination centre, Saint-Denis

Claude Guiguen – claude.guiguen@univ-rennes1.fr
Parasitologist, Rennes

Yves Hatchuel – Yves.Hatchuel@chu-fortdefrance.fr
Pediatra, Fort-de-France

Claude Hengy – claudie.hengy@orange.fr
Biologiste, International vaccination centre, Lyon

Arezki Izri – arezki.izri@avc.aphp.fr
Parasitologist, medical entomologist, Bobigny

Dominique Jean – djean@chu-grenoble.fr
Pediatra, Grenoble

Frédéric Jourdain – frederic.jourdain@sante.gouv.fr
Health engineer, Paris

Isabelle Lamaury – isabelle.lamaury@chu-guadeloupe.fr
Infectiologist, Pointe-à-Pitre

Bruno Marchou – marchou.b@chu-toulouse.fr
Infectiologist, Toulouse

Valérie Masson – dr.masson@club-internet.fr
General practitioner, Lille

Philippe Minodier – philippe.minodier@ap-hm.fr
Pediatra, Marseille

Alice Perignon – alice.perignon@psl.aphp.fr
General practitioner, Paris

Sylvie Piccoli – sylvie.piccoli@wanadoo.fr
General practitioner, tropical medicine, Arbonne

Béatrice Quinet – beatrice.quinet@trs.aphp.fr
Pediatra, Paris

André Yebakima – yebakima@cg972.fr
Medical entomologist, Fort-de-France

TRANSLATION INTO ENGLISH

Julien Santi-Rocca – julien.santi-rocca@cbm.uam.es
Biologist, Madrid, Spain

Sherri Smith
Biologist, Paris

Parasite, 2011, 18, 93-111